ERCC1、BAG-1及BRCA1基因在非小细胞肺癌中的表达及其与预后的关系

Expression and prognostic significance of ERCC1 BAG-1 and BRCA1 mRNA in non-small cell lung cancer

目的探讨ERCC1、BAG-1和BRCA1基因mRNA在接受以铂类为基础辅助化疗的非小细胞肺癌(non-small cell lung cancer,NSCLC)患者中的表达情况及其与预后的关系。方法 85例NSCLC患者中74例给予以铂类为基础的术后辅助化疗,采集全组患者的肿瘤组织和其中34例患者的癌旁组织,应用半定量RT-PCR法,检测其ERCC1、BAG-1和BRCA1基因mRNA的表达情况,回顾性分析患者的临床病理资料,探讨3个基因的表达与患者总生存期(OS)之间的关系。结果①ERCC1、BAG-1阴性表达的患者OS显著长于阳性表达的患者(P均=0.001)。ERCC1、BAG-1阴性表达的患者接受铂类化疗的疗效显著优于阳性表达的患者(P=0.002、P=0.001)。②BRCA1阴性表达的患者OS长于阳性表达的患者,但差异无统计学意义(P=0.057)。③多因素分析显示ERCC1、BAG-1可作为NSCLC患者接受铂类化疗的预后指标(P=0.027、P=0.022)。结论检测ERCC1和BAG-1的表达可作为指导NSCLC患者术后接受铂类化疗及预后评估的指标。

Objective To investigate the expression and prognostic usefulness of ERCC1,BAG-1 and BRCA1 in patients with non-small cell lung cancer（NSCLC） treated with platinum-based adjuvant chemotherapy. Methods RT-PCR was used to investigate the mRNA expression of ERCC1,BAG-1 and BRCA1 in 85 samples of NSCLC tissues and 34 tumor-adjacent tissues.Relationships of the expression of these three genes with overall survival（OS） were analyzed. Results ①OS was significantly longer in patients negative for ERCC1 or BAG-1 mRNA expression than in those positive for expression of either gene（P=0.001）.Platinum-based chemotherapy was more effective for patients negative for ERCC1 or BAG-1 than for the corresponding positive patients（P=0.001 and P=0.002）, respectively.②OS may be longer in patients negative for BRCA1 mRNA expression than in BRCA1-positive patients （P=0.052）. ③Multivariate analysis suggests that ERCC1 and BAG-1 may be prognostic indicators for patients receiving platinum-based adjuvant chemotherapy（P=0.027 and P=0.022）. Conclusion Expression of ERCC1 and BAG-1 mRNA may be useful in the prognosis of NSCLC treated with platinum.